Skip to main content
. Author manuscript; available in PMC: 2022 Aug 1.
Published in final edited form as: Mol Cancer Ther. 2021 Nov 17;21(2):322–335. doi: 10.1158/1535-7163.MCT-21-0344

Figure 5.

Figure 5.

The merestinib/capmatinib combination shows efficacy and tolerability in vivo. A, A box plot of volume of tumors harvested from mice on day 18 of treatment. *, # denote significance. B, Plot of body weight percent change of treated mice as a function of treatment time. C, The individual contribution of each TPR-MET mutant was determined by ddPCR at the end of the study and expressed as percent tumor volume. Each bar represents an individual treatment subject.